Pharmaceutical Insights

30 September 2009

Welcome to the September edition of Pharma Insights. In this edition, we consider the proposed amendments to the Medicines Australia Code of Conduct and whether a single Code of Conduct should apply across the therapeutic goods industry. What does this mean for you?

We also consider the recent critical round of regulatory reforms in relation to therapeutic goods, and the enforcement of consumer protection laws.

We then turn our attention to duties owed by doctors to third parties and, given the northern summer of developments in Europe, provide an update on issues of interest for Australian pharma.

There was movement at the station: the Australian consumer law reforms are being enacted into law

By Madeleine Kearney and Jocelyn Kellam.

While the precise impact of Australia's consumer law reforms on the pharmaceutical and medical device industries cannot be determined at this stage, say Madeleine Kearney and Jocelyn Kellam, it will definitely have an effect - especially on regulatory action.

What's up doc? The doctor's duty of care to third parties

By Greg Williams and Mandi Chonowitz.

Does a doctor owe a duty of care to third parties who are not patients, but who might conceivably be affected by his or her treatment of a patient? Greg Williams and Mandi Chonowitz look at the cautious approach to this taken by Australian courts.
Key Contacts

To view claytonutz.com correctly, you should upgrade your browser

Download Google Chrome
Download Firefox
Download Safari
Download Internet Explorer